JC18 Rec'd PCT/PTO 3 1 DEC 2001



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of RHOLAM ET AL.

Examiner:

**UNASSIGNED** 

Art Unit:

**UNASSIGNED** 

Serial No.: 09/701,945

Filed:

**DECEMBER 5, 2000** 

Title:

POLYPEPTIDES WHICH POSSESS

AN ACTIVITY OF THE  $\beta$ -

**SECRETASE TYPE** 

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents Washington, D.C. 20231

Sir:

 $\boxtimes$ 

In furtherance of requirements set forth in 37 C.F.R. 1,56, 1.97 AND 1.98 Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the

	Con	missioner thorized to charge any fees under 3 .R. 1.17(p) or credit any
	over	payment to Account No. 18-1982.
(b)	This	Information Disclosure Statement is filed after the period set forth in 37 C.F.R.
	1.97	b), but is believed to be filed before the mailing date of a final action under §1.113 or
	a no	ice of allowance under §1.311, whichever occurs first.
	(1)	The undersigned attorney certifies that each item of information contained in this
		Information Disclosure Statement was cited in a communication from a foreign pater
		office in a counterpart foreign application not more than three months prior to the
		filing of this statement;
	(2)	The undersigned attorney certifies that no item of information contained in this
		Information Disclosure Statement was cited in a communication from a foreign pater
		office in a counterpart foreign application or, to the knowledge of the undersigned
		attorney after making reasonable inquiry, was known to any individual designated in
		§1.56(c) more than three months prior to the filing of this statement; or
	(3)	This Information Disclosure Statement is accompanied by a transmittal letter in
		which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is
		authorized.
		Respectfully submitted,
		Mill Copple
		William C. Coppola, Reg. No. 41,686
		Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626

Attorney Docket No.: ST98014A

October 30, 2001

OTPE

Appro use through 10/31/99. OMB 0651-0031 U.S. DEPARTMENT OF COMMERCE

nder the Paperwork Reduction Act of 1995, no pe	ersons are required to respond to collect	tion of information unless it contains a valid OMB co	ntrol numb
Substitute for form 1449A/PTO	FIRM & TO A PENEMENT	Complete if Known	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	

AMERICA	Complete if Known	
Application Number	9/701,945	
Filing Date	12-05-2000	
First Named Inventor	RHOLAM	
Group Art Unit		
Examiner Name		
Attorney Docket Number	ST98014 A	

	U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.1	U.S. Paten Number	t Document  Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
					_			
					<del>  </del>			
			<del>-    </del>					
			$\longrightarrow$					
ļ		<del></del>	-++					
<b></b>					<del>                                     </del>			
<u> </u>			- + +					
<b></b>			- + - †					
	<b>—</b>							

				FORE	IGN PATENT DOCUMENT	S			
Examiner Initials*	Cite No.1			Foreign Patent Do	Kind Code <sup>5</sup>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	т6
		Office <sup>3</sup>	Number <sup>4</sup>	(if known)	Applicant of once programment	MM-DD-YYYY	Figures Appear	<b> </b>   "	
								$\bot$	
								4	
								+	
						<b>_</b>		-	
						ļ		+	
								+	
								+	
						<u> </u>		┸	

Examiner	 Date	
Signature	Considered	
Cignataro		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside thi
--



PTO/SB/08B (10-96)
se through 10/31/99. OMB 0651-0031
U.S. DEPARTMENT OF COMMERCE
ction of information upper its program of information upper in the company of information upper its program of infor

Substitut	e for form 1449R/i	PTO	WY & THAT	EMA: Co	mpl te if Kn wn	
				Application Number	9/701,945	
INFO	ORMATIC	)N D	ISCLOSURE	Filing Date	12-05-2000	
INFORMATION DISCLOSUR STATEMENT BY APPLICAN  (use as many sheets as necessary)	ΔΡΡΙΙΚΑΝΤ	First Named Inventor	RHOLAM			
UIA	1 5 14 1 5 14 1	<b>.</b>	AI I LIOAIII	Group Art Unit		
	(use as man	y sheets	s as necessary)	Examiner Name		
Sheet	1	of	2	Attorney Docket Number	ST98014 /	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>					
	A\$	EVIN Genevieve et al., Alzheimer's Disease Amyloid Precursor Protein (ABPP): Proteolytic Processing, Secretases and BA4 Amyloid Production, Amyloid:Int. J Exp Clin. Invest I, 263-280 (1994)						
-								
_								
Examine		Date Considered						

considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.